ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

ClinicalTrials.gov ID: NCT03059992

Public ClinicalTrials.gov record NCT03059992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Study identification

NCT ID
NCT03059992
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Scynexis, Inc.
Industry
Enrollment
233 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2017
Primary completion
Aug 24, 2023
Completion
Aug 24, 2023
Last update posted
Nov 19, 2024

2017 – 2023

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294-0006
UC Davis Medical Center Sacramento California 95817
University of California San Francisco San Francisco California 94143
Emory University Hospital Midtown Atlanta Georgia 30322
Augusta University Augusta Georgia 30912
Massachusetts General Hospital Boston Massachusetts 02114
University of Michigan Ann Arbor Michigan 48109
Wayne State University Detroit Michigan 48201
University of Minnesota Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Washington University School of Medicine St Louis Missouri 63110
Memorial Sloan Kettering Cancer Center New York New York 10021
Weill Cornell Medical College New York New York 10065
Stony Brook University Medical Center Stony Brook New York 11794
Duke University Medical Center Durham North Carolina 27710
Wake Forest Baptist Medical Center Winston-Salem North Carolina 27157
University of Pittsburg Medical Center Pittsburgh Pennsylvania 15203
University of Texas Southwestern Medical Center Dallas Dallas Texas 75390-8589
University of Texas Health Science Center at Houston Houston Texas 77030
University of Wisconsin Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03059992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2024 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03059992 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →